A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
Conclusion Tarextumab was generally well-tolerated at doses<2.5 mg weekly and 7.5 mg/kg every other and every third week. Diarrhea was dose-limiting above these levels, but relatively easily managed at lower doses. Inhibition of Notch pathway signaling was demonstrated at these doses.ClinicalTrials.gov Identifier: NCT01277146.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anorexia | Cancer & Oncology | Constipation | Drugs & Pharmacology | Eating Disorders & Weight Management | Gastroenterology | Genetics | Investigational New Drugs | Pain | Stem Cell Therapy | Stem Cells | Study | Toxicology